A multi-centre, single arm, open-label extension study to evaluate the long-term safety of GSK3511294 (Depemokimab) in adult and adolescent participants with severe asthma with an eosinophilic phenotype from studies 206713 or 213744

Quick answer

A multi-centre, single arm, open-label extension study to evaluate the long-term safety of GSK3511294 (Depemokimab) in adult and adolescent participants with severe asthma with an eosinophilic phenotype from studies 206713 or 213744 for Severe asthma with an eosinophilic phenotype is a Phase 3 program (other) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).